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ABSTRACT
Background. Circulating endothelial progenitor cells
(cEPCs) as recruited to the angiogenic vascular system of
malignant tumors have been proposed as a biomarker in
malignancies. The effect of antitumor chemotherapy on
cEPCs is not fully understood. We examined the level of
cEPCs, vascular endothelial growth factor (VEGF), and
angiopoietin-2 in the blood of sarcoma and melanoma patients
before and after isolated limb perfusion (ILP) with or without
recombinant human tumor necrosis factor-a (rhTNF-a).
Methods. Twenty-two patients, 11 each with soft tissue
sarcoma or recurrent melanoma of the limb, were recruited.
ILP was performed with rhTNF-a/melphalan (TNF) or
melphalan only (no TNF). Fifteen healthy volunteers
served as control subjects. Blood was sampled before and
up to 6 weeks after ILP. Peripheral blood mononuclear
cells were isolated by density gradient centrifugation, and
annexin V-negative cells were characterized as cEPCs by
triple staining for CD133?, CD34, and VEGFR-2?.
Results. Before treatment, cEPC numbers were significantly
increased in sarcoma (0.179 ± 0.190 %) and melanoma
patients (0.110 ± 0.073 %) versus healthy controls
(0.025 ± 0.018 %; P \ 0.01), but did not differ significantly
between sarcoma and melanoma patients. cEPC decreased
significantly after ILP in patients with no TNF compared to
pretreatment values (P \ 0.05) and were significantly lower
at 4 h, 48 h, and 1 week compared to ILP with TNF
(P \ 0.05). Values 6 weeks after ILP were significantly lower
than before ILP in both investigated groups (P \ 0.01).
Conclusions. ILP with TNF results in activation of bone
marrow–derived EPCs compared to ILP without TNF.
Alteration of cEPCs and angiopoietin-2 by rhTNF-a might
account for the cytotoxicity and hemorrhagic effects on
tumor vessels during limb perfusion procedures.
Isolated limb perfusion (ILP) with recombinant human
tumor necrosis factor-a (rhTNF-a, or tasonermin) and mel-
phalan is a highly effective treatment for soft tissue sarcoma and
in-transit metastases of malignant melanoma of the extremities.
In a neoadjuvant setting, ILP contributes to radical resection of
locally advanced sarcomas and long-term limb salvage.1–3
One of the major systemic side effects of rhTNF-a
treatment is the induction of a systemic inflammatory
response syndrome (SIRS), in which patients may develop
tachycardia and fever as a result of increased cardiac output
and decreased vascular resistance.3–5 The incidence and
severity of SIRS correlates with the subsequent activation
of the cytokine network and the occurrence of leakage from
the limb to the systemic circulation.2 Regionally, the
application of rhTNF-a yields an endothelial damage of
tumor vessels with destruction of microcirculation and
consecutive development of tumor necrosis.6,7 To our
knowledge, the effect of rhTNF-a on bone marrow–derived
(BMD) endothelial progenitor cells has not yet been
described.
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Tumor vascularization is dependent on the sprouting of
nearby blood vessels, with migration and differentiation of
existing mature endothelial cells (angiogenesis). Several
studies have provided evidence that tumor vasculature can
also arise through vasculogenesis, a process by which
BMD endothelial progenitor cells (EPC) are recruited and
differentiate into mature endothelial cells to form new
blood vessels.8,9 Hematopoietic (VEGFR-1?) and endo-
thelial (VEGFR-2?) BMD progenitors collaborate in
disease progression, first by initiating the premetastatic
niche and second by promoting the vascularization of
metastatic lesions.10–12
Although a close interplay between EPCs and tumor
neovascularization is suggested, the exact role of EPCs to
the pathogenesis of undifferentiated tumors with high
proliferation rates remains to be determined.13 Monitoring
and targeting BMD endothelial progenitors is of interest to
guide the optimal use of target therapies in patients.13–15 In
this regard, the effect of rhTNF-a on BMD endothelial
progenitor cells has not yet been studied.
We investigated the effect of a local administered drug
combination targeting the tumor vasculature for antitumor
treatment of ILP with rhTNF-a versus ILP with
chemotherapy alone on cEPC in melanoma and high-grade
sarcoma patients. Beside clinical parameters, the cEPC
mobilizing factors vascular endothelial growth factor
(VEGF) and angiopoietin were determined in blood to
gather further information. We also assessed associated
pathophysiologic changes affecting cEPC subordinate to
applied drugs for antitumor treatment.
METHODS
Patients
Eleven patients with high-grade soft tissue sarcoma
(4 men, 7 women) and 11 patients with in-transit metasta-
sized melanoma (3 men, 8 women) were enrolled onto this
study. Patient characteristics are listed in Table 1. ILP with
rhTNF-a/melphalan was used for in-transit metastasized
melanoma (n = 5) and G3 sarcoma (n = 11) to be compared
to ILP after treatment with cisplatin/melphalan alone for in-
transit metastasized melanoma (n = 6). Exclusion criteria
for the study were cardiogenic, septic, or hemorrhagic shock
within the last 6 months; and pneumonia or a history of acute
respiratory distress syndrome, pleural empyema, or any
TABLE 1 Patients treated with ILP with or without TNF
ILP with: Disease Sex Age (y)a Tumor type Location
TNF (2 mg) Sarcoma (n = 11) F 65 Malignant fibrous histiocytoma G3 Left lower limb
Melphalan (10 mg/L
perfused limb volume)
F 56 Malignant fibrous histiocytoma G3 Left elbow
M 54 Dedifferentiated liposarcoma G3 Left thigh and knee
F 40 Undifferentiated sarcoma G3 Right thigh and knee
M 22 Epithelioid sarcoma G3 Left fore foot
M 72 Myxofibrosarcoma G3 Left lower limb
F 37 Synovial sarcoma Right knee
F 71 Myxoid liposarcoma G3 Left lower limb
M 67 Epithelioid sarcoma G3 Right forearm
F 34 Myxoid liposarcoma G3 Right thigh
F 34 Liposarcoma G3 Left forearm
Melanoma (n = 5) F 59 In-transit metastasizing MM Right lower limb
M 85 In transit metastasizing MM Left lower limb
M 51 In-transit metastasizing MM Right lower limb
F 75 In-transit metastasizing MM Left lower limb




melanoma (n = 6)
F 69 In-transit metastasizing MM Right lower limb
M 36 In-transit metastasizing MM Right lower limb
F 75 In-transit metastasizing MM Left lower limb
F 45 In-transit metastasizing MM Left lower limb
F 75 In-transit metastasizing MM Left lower limb
F 51 In-transit metastasizing MM Left lower limb
ILP isolated limb perfusion, TNF recombinant human tumor necrosis factor-a, MM malignant melanoma
a No significant differences concerning age were observed between the treatment groups
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other sign of infection. None of the patients received con-
current medication known to influence the mobilization of
cells from the bone marrow (i.e., hydrocortisone, ACE
inhibitors, statins) at the time of blood sampling. For con-
trols, we recruited 15 healthy volunteers from our laboratory
staff. Informed consent was obtained from all study partic-
ipants. The study was approved by the ethics committee of
the University of Heidelberg.
Isolation Perfusion and Application of Drugs
The perfused limb volume was measured with the water
displacement method.16 The detailed method of ILP has
been described previously.17 Shortly after exposition and
cannulation of the major artery and vein of the limb,
extracorporeal circulation was established with a roller
pump and heat exchanger (Jostra HL 20, Maquet,
Germany). Gas exchange was achieved with a bubble
oxygenator (Baxter, Utrecht, The Netherlands). The per-
fusate temperature ranged from 39 C to 43 C, and the
volume of the perfusate was kept constant at approximately
700 ml. Tissue temperature was measured by needle
probes inserted to healthy muscle and tumor tissue and was
intended to be C38 C and kept \40.5 C. Perfusion time
was 90 min. Leakage control was performed by injection
of indium-111-labeled autologous erythrocytes and 99mTc-
labeled albumin to the limb circuit and continuous moni-
toring of the systemic circulation. After perfusion, the limb
was rinsed with 3 L of hydroxyethyl starch until no further
reduction of the radiopharmaceutical activity in the limb
was achievable. rhTNF-a (Boehringer Ingelheim, Ingel-
heim, Germany) was provided at a dose of 2 mg (upper
limb) or 3 mg (lower limb). The melphalan dosage was
10 mg/L of perfused limb volume, as described previously.
Blood Sampling
In patients and healthy controls, 25 ml of blood was
obtained by insertion of a 20-gauge cannula intravenously
and collected in tubes containing sodium citrate (0.105 M)
as an anticoagulant. Blood samples from patients were
collected before ILP and 2 h, 4 h, 24 h, 48 h, 1 week, and
6 weeks after ILP.
Flow Cytometry
All blood samples were processed within 1 h after col-
lection. Peripheral blood mononuclear cells (PBMCs) were
prepared by density gradient centrifugation with Ficoll-
Hypaque (Amersham Biosciences, Freiburg, Germany).
The expression of cell-surface antigens was determined by
four-color immunofluorescence staining as described pre-
viously.14,18 Briefly, 100 ll of PBMC (containing 1 9 106
cells) were incubated with 10 ll of FcReceptor-blocking
reagent (Miltenyi Biotec, Bergisch-Gladbach, Germany)
for 10 min to inhibit nonspecific bindings. The cells were
then incubated at 4 C for 30 min with 10 ll phycoerythrin
(PE)-conjugated anti-human CD133 monoclonal antibodies
(mAb) (Miltenyi Biotec, Bergisch-Gladbach, Germany),
10 ll Peridinin Chlorophyll Protein Complex (PerCP)-
conjugated anti-human CD34 mAb (BD Biosciences,
Heidelberg, Germany), 10 ll allophycocyanin (APC)-
conjugated vascular endothelial growth factor receptor
(VEGFR)-2 mAb (R&D Systems, Wiesbaden-Nordenstadt,
Germany) and 10 ll fluorescein isothiocyanate (FITC)-
conjugated annexin V mAb (BD Biosciences, Heidelberg,
Germany). PE-, PerCP-, APC-, and FITC-conjugated
isotype-matched immunoglobulin (Ig)-G1 and IgG2a anti-
bodies (DakoCytomation, Hamburg Germany) were used
for each patient and measurement as negative controls. The
cells were washed three times to remove unbound anti-
bodies and finally resuspended in 400 ll of fluorescence-
activated cell sorting (FACS) solution (BD Biosciences,
Heidelberg, Germany). FACS analysis was performed on a
FACSCalibur flow cytometer (BD Biosciences, Heidel-
berg, Germany) and the data were analyzed by WinMDI
28 software (developed by Joseph Trotter at the Scripps
Research Institute, La Jolla, CA). A minimum of 500,000
events were collected. FACS analysis of each probe was
performed in triplicate. The frequency of cEPCs in
peripheral blood was determined by a two-dimensional
side-scatter/fluorescence dot-plot analysis of the samples
after exclusion of annexin V–positive cells and appropriate
gating. The exclusion of annexin V–positive cells was
performed to exclude contamination with apoptotic cells in
our positive population. EPC counts are expressed as a
percentage of total PBMCs in each patient or control
subject.
Enzyme-linked Immunosorbent Assay
Serum concentration of VEGF and angiopoietin-2
(Ang-2) was assessed with an enzyme-linked immunosor-
bent assay kit (R&D Systems) in triplicate samples obtained
from 5 ml of serum. Enzyme-linked immunosorbent assay
was performed according to the manufacturer’s instructions.
Statistical Analysis
Data analyses were performed by SPSS software, ver-
sion 20.0 (SPSS, Chicago, IL). For inner-group comparison
at different time points and intergroup comparison, the
Kruskal–Wallis test was followed by post hoc testing
(Kolmogorov–Smirnov test). The Mann–Whitney U-test
was used for pairwise comparisons.
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P \ 0.05 was considered to be statistically significant.




Eleven patients with G3 soft tissue sarcoma (3 men), 11
patients with in-transit metastasized melanoma (3 men),
and 15 healthy volunteers were enrolled onto this study.
Patient characteristics are listed in Tables 1 and 2.
There was no statistical difference in mean age between
the ILP with rhTNF-a and melphalan (55 ± 20 years), the
ILP with chemotherapy alone (59 ± 17 years), and the
healthy volunteers (42 ± 13 years).
Circulating Endothelial Progenitor Cells (cEPC)
before Treatment
The percentage of the hematopoietic stem cells, defined as
positive staining for CD34 and CD133, was significantly
increased in in-transit metastasized melanoma (0.30 ±
0.10 %) and soft tissue sarcoma (0.48 ± 0.12 %) patients
compared to the healthy controls (0.13 ± 0.04 %; P \ 0.001
each, Fig. 1). The percentage of VEGFR-2? cells within the
population of CD34?/CD133? cells was measured, thereby
defining cEPCs in our study. These findings correspond to
cEPC in sarcoma patients of 0.179 ± 0.190 % and in mela-
noma patients of 0.110 ± 0.073 % versus healthy controls of
0.025 ± 0.018 % (Table 2, Fig. 1; P \ 0.01 each).
VEGF and Ang-2 Levels before Treatment
We found significantly increased mean VEGF levels in
both sarcoma and melanoma patients (sarcoma
359 ± 157 pg/ml, melanoma 310 ± 303 pg/ml) in com-
parison to healthy controls (27 ± 13 pg/ml; P = 0.001
each). No differences between the treatment groups and the
tumor type were observed before treatment (Table 2).
Ang-2 levels before treatment were significantly lower in
healthy controls (1665 ± 445 pg/ml) compared to sarcoma
(2929 ± 960 pg/ml, P = 0.033) and melanoma (2564 ±
665 pg/ml, P = 0.045) patients. In regard to VEGF and Ang-2
levels, no differences between the two treatment groups and
between the tumor types were observed before treatment
(Table 2).
Effect of ILP with rhTNF-a versus Chemotherapy Alone
on cEPC
In ILP with rhTNF-a, cEPC levels were higher compared to
ILP with chemotherapy at time points 4 h (TNF 0.252 ±
0.206 %; no TNF 0.034 ± 0.018 %; P = 0.037), 24 h (TNF
0.180 ± 0.186 %; no TNF 0.031 ± 0.019 %; P = 0.069),
48 h (TNF 0.118 ± 0.081 %; no TNF 0.032 ± 0.022 %;
P = 0.037), and 1 week (TNF 0.048 ± 0.023 %; no TNF
0.026 ± 0.011 %; P = 0.023, Table 3, Fig. 2).
Comparison between pre- and posttreatment cEPC levels
showed significant changes in cEPC numbers. After ILP with
chemotherapy alone, cEPC numbers decreased significantly
from pretreatment values (basal 0.102 ± 0.046 %) more
than 50 % within the first 4 h (4 h, 0.034 ± 0.018 %;
P = 0.031) until the end of the observation period (6 weeks,
0.023 ± 0.011 %; Table 3, Fig. 2; P = 0.001).
The changes in cEPC numbers after ILP with rhTNF-a
were followed by an overall normalization after 1 week.
Six weeks after ILP, cEPC in rhTNF-a were significantly
decreased compared to pretreatment values (P = 0.005).
After 6 weeks, no difference between the two treatment
groups was observed (Fig. 2).
Effect of ILP with rhTNF-a versus Chemotherapy Alone
on VEGF and Ang-2
In ILP with rhTNF-a, VEGF serum levels were signif-
icantly decreased 2 h after ILP (123 ± 119 pg/ml;
P = 0.036) and significantly elevated 1 week after ILP
(606 ± 280 pg/ml; P = 0.011) compared to values before
ILP treatment (375 ± 231 pg/ml, Table 3, Fig. 3). VEGF
serum levels were elevated in ILP with rhTNF-a, although
without a statistically significant difference, compared to
patients after ILP without rhTNF-a (Table 3, Fig. 3).
TABLE 2 cEPC, VEGF, and Ang-2 levels before treatment
Group n Mean ± SE of:
cEPC (% of PBMC) VEGF (pg/ml) Ang-2 (pg/ml)
Sarcoma 11 0.179 ± 0.190 359 ± 157 2929 ± 960
Malignant melanoma 11 0.110 ± 0.073 310 ± 303 2564 ± 665
Healthy controls 15 0.025 ± 0.018** 27 ± 13* 1665 ± 445***
cEPC circulating endothelial progenitor cell, VEGF vascular endothelial growth factor, Ang-2 angiopoietin-2, PBMC peripheral blood mono-
nuclear cell
* P \ 0.001, ** P \ 0.01, *** P \ 0.05 vs. sarcoma and malignant melanoma
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The course of Ang-2 levels in ILP with rhTNF-a dif-
fered significantly compared to ILP with cisplatin/
melphalan from the time point 2 h (TNF 3248 ± 1009 pg/ml;
no TNF 1585 ± 665 pg/ml, P = 0.003) until the end of the
observation period after 6 weeks (TNF 3094 ± 469 pg/ml;
no TNF 2197 ± 415 pg/ml; P = 0.002, Table 3, Fig. 4). In
rhTNF-a-treated patients, a significant peak of Ang-2 was
observed at 24 h (6024 ± 2085 pg/ml, P = 0.000), 48 h
(6286 ± 2117 pg/ml, P = 0.001), and 1 week (4555 ±
762 pg/ml, P = 0.001) compared to values before ILP
(2929 ± 960 pg/ml). Within the no-TNF group, a significant
increase of Ang-2 was observed 24 h after ILP (3404 ±
417 pg/ml, P = 0.031) compared to basal values (2402 ±
606 pg/ml, Table 3, Fig. 4).
After treatment, no significant differences were
observed between the tumor types studied.
DISCUSSION
The study of antiangiogenic strategies are progressing
quickly, with the aim of limiting and/or inhibiting tumor
progression. Until now, no marker exists to monitor the
effect of antiangiogenic treatment as an anticancer
therapy.19
We describe what is to our knowledge the first quantita-
tive analysis of subsets of circulating VEGFR-2? BMD
progenitor cells in the peripheral blood of sarcoma and
melanoma patients undergoing ILP. This study demonstrates
an increased mobilization of cEPCs in both sarcoma and
melanoma patients compared to healthy individuals. We
found that levels of cEPC defined by CD133, CD34, and
VEGFR-2 were significantly higher during early reperfusion
in ILP with TNF-a compared to ILP with chemotherapy
alone. In parallel, serum concentrations of Ang-2 were found
to undergo significant changes after ILP. A significant
increase of Ang-2 in ILP with rhTNF-a was observed 24 and
FIG. 1 CD133- and CD34-positive cells in PBMC in healthy
controls compared to sarcoma and melanoma patients before treat-
ment. CD133- and CD34-positive cells in PBMC are significantly
increased in sarcoma and in-transit metastasized melanoma patients
compared to healthy controls (*P \ 0.01 vs. healthy controls). Data
are displayed as mean ± SD; P \ 0.05 was considered to be
statistically significant
FIG. 2 cEPC before and after ILP with or without rhTNF-a. cEPC
did not differ significantly before ILP (basal) between the investigated
groups. The amount of cEPC was significantly higher 4 and 48 h after
ILP with rhTNF-a (TNF) compared to melphalan and cisplatin (no
TNF) (*P \ 0.05). Compared to basal values, cEPC were signifi-
cantly lower in no TNF starting at 2 h after ILP and 1 and 6 weeks in
TNF after ILP (#P \ 0.05). Data are displayed as mean ± SEM;
P \ 0.05 was considered to be statistically significant
FIG. 3 VEGF in patient serum before and after ILP with TNF or
without TNF (no TNF). VEGF in serum did not show significant
differences between the investigated groups before and after ILP. In
rhTNF-a (TNF)-treated patients, VEGF serum levels decreased
significantly at 2 h after ILP compared to pretreatment values (basal;
#P = 0.036). One week after ILP, a significant increase was observed
compared to basal values in the TNF group (*P = 0.011). Data are
displayed as mean ± SEM; P \ 0.05 was considered to be statisti-
cally significant
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48 h after ILP compared to pretreatment values in that group
(Fig. 4). This means that ILP with rhTNF-a in combination
with melphalan might mobilize VEGFR-2-positive progen-
itors from the bone marrow, followed by Ang-2 expression of
EPCs or endothelium. A big part of the explanation must be
the consequence of rhTNF-a treatment, causing a higher
degree of ischemia and anoxia in the perfused limb. Reper-
fusion results in a higher risk for severe ischemia–
reperfusion injury.20 Increased Ang-2 has been reported in
response to ischemia–reperfusion and hypoxia.20,21
Increased Ang-2 has also been shown to be associated with
increased endothelial apoptosis.
Growing evidence suggests that BMD EPCs circulate in
the blood and play an important role in the formation of
new blood vessels.22,23 Moreover, it is now established that
tumor vasculature is not necessarily only derived from
endothelial cell sprouting; instead, cancer tissue can
acquire its vasculature by alternative mechanisms.24 Stud-
ies in animals show that EPCs participate in tumor
angiogenesis, thereby enhancing tumor growth.25 Mobili-
zation of cEPCs from the bone marrow critically depends
on the activation of metalloproteinases and up-regulation
of adhesion molecules. This is most likely mediated by
soluble factors such as VEGF. EPCs provide both
instructive (release of proangiogenic cytokines) and struc-
tural (vessel incorporation and stabilization) functions that
contribute to the initiation of neoangiogenesis.26,27
However, the lack of a consensual definition of EPC
complicates the interpretation of work in this field.
We have used standard flow cytometry to detect cEPCs,
although different approaches have been applied in a variety
of patient populations.14,28–31 Among these, flow cytometry
and colony-forming assays are the most used methods for
quantifying cEPCs. Both of these techniques, however, have
serious limitations. Although endothelial cell colony-form-
ing units (CFUs) are widely accepted as an estimate of EPC
number and function in cell culture, some important limita-
tions may restrict the assumption that endothelial cell CFUs
accurately reflect EPC numbers. Shantsila et al., comparing
CFU units to flow cytometry, noted that endothelial cell CFU
counts represent the cumulative characteristics of EPC
quantity and their functional characteristics, and cannot be
reliably used for the estimation of EPC numbers in peripheral
blood or bone marrow.32 They conclude by suggesting that
flow cytometry may be the best technique for EPC quanti-
fication. Although the exact phenotype of cEPCs is still
controversially discussed, the presence of CD34, CD133,
and VEGFR-2 seems to be well supported and is therefore
used in this study.29,33
Recent evidence, however, calls into question the ability
of BMD EPC to act as a bona fide precursor for adult
vasculogenesis.34 Wickersheim et al. demonstrated in a
murine model that local VEGF production induces a
massive infiltration of BMD cells in tumors but does not
lead to vessel wall integration of these cells, suggesting
that during tumor progression, vascularization occurs pri-
marily via classical tumor angiogenesis.35 In contrast,
several groups reported significant incorporation of bone
marrow EPCs into the vessel wall of tumors.15,36 In brief,
cEPC could be part of both tumor vascularization, inducing
paracrine effects on the growth and progression of tumors.
Tissue hypoxia present in tumors is considered to be
central to this paracrine mechanism. VEGF expression is
increased locally within the hypoxic tissue itself, and that
in turn stimulates the recruitment of progenitor cells to the
hypoxic site.23,37 Many factors are described to play
important roles in mobilizing EPCs.22,38 Among them are
growth factors, such as VEGF, placental growth factor,
erythropoietin, and Ang-2; proinflammatory cytokines such
as granulocyte macrophage colony-stimulating factor and
granulocyte-colony stimulating factor; chemokines such as
stromal cell-derived factor 1; hormones such as estrogens;
lipid-lowering and antidiabetic drugs; and physical activity.
It has been shown that the serum concentration of VEGF
correlates with the concentration of EPCs in cancer tis-
sue.38 We recently observed a correlation of serum VEGF
and cEPC in lung cancer patients.14 Fu¨rstenberger et al.
observed in patients with primary breast cancer that Ang-2
and VEGF were concomitantly increased with cEPC,
suggesting a mobilization by neoadjuvant chemotherapy.39
FIG. 4 Ang-2 serum levels in patients before and after ILP with TNF
or without TNF (no TNF). No significant differences in Ang-2 levels
were observed before treatment within the tumor types melanoma and
sarcoma and the treatment groups of ILP with rhTNF-a (TNF)
compared to cisplatin and melphalan alone (no TNF). After ILP,
Ang-2 differed significantly at all points of measurement between the
two treatment groups, TNF and no TNF (#P \ 0.021). A significant
increase compared to basal values was found 24 h, 48 h, and 1 week
after ILP in the TNF group (*P \ 0.001). In no TNF patients were
Ang-2 levels significantly higher 24 h after ILP compared to basal
values (9P \ 0.05). Data are displayed as mean ± SEM; P \ 0.05
was considered to be statistically significant
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The mean contribution of EPCs to human tumor vas-
culature in transplantation studies ranged from 1 % to
12 %.40 Purhonen et al. reported in animal models that
BMD or other endothelial precursors did not contribute to
tumor vasculature at all.41 As proof that the significant
intraluminal incorporation of EPC into tumor vasculature is
challenging, the biological role of EPC in tumor angio-
genesis was often questioned. Several reports demonstrate,
however, that the specific ablation of BMD EPC results in
significant impaired tumor growth and vascularization.36,42
It is a matter of discussion that even with low vessel
incorporation, the paracrine effects of EPC may be critical
for tumor angiogenesis. Therefore, the differences in EPC
incorporation in previously published reports may not only
be due to the diversity of tumor models and types studied,
but also to the temporal differences in tumor development
at the time of study.23
The induction of cEPC after ILP with TNF-a and mel-
phalan can be specifically attributed to rhTNF-a, as we
have demonstrated that ILP with cytostatic drugs alone
induced a significant decrease in cEPC starting 4 h after
ILP. After a period of 6 weeks after ILP, cEPC were sig-
nificantly lower in both investigated groups than before
treatment and did not differ from values of healthy vol-
unteers. In our series, significant differences were observed
between the treatment regimen of ILP. No differences in
principle between the different tumor types have been
observed. Although VEGF levels tended to be higher in
rhTNF-a-treated patients, no significant difference was
observed. However, cEPC and Ang-2 levels were signifi-
cantly higher at different points of measurements in
rhTNF-a patients.
From the observations in our study, we conclude that
increased amounts of cEPCs are recruited in sarcoma and
in-transit metastasized melanoma patients, most likely for
vasculogenesis and paracrine effects, which stimulate
angiogenic activity of resting mature endothelial cells.
Moreover, our study suggests an association of cEPC
numbers with the applied therapeutic agents via ILP.
EPCs may exert an important function as an endogenous
stimulus of tumor vasculogenesis. Further studies have to
be conducted to reveal whether EPC counts could be a
useful tool to decide whether to continue current treatment,
thus limiting the use of inefficient and costly therapies.
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